CraniUS CEO Mike Maglin was honored to take the stage at LSIUSA25 to share how the company is reimagining drug delivery. Presenting our latest advancements and vision for the future of neurotherapeutics to such an incredible group of innovators, investors, and thought leaders was a major milestone.

From tackling the blood-brain barrier to redefining patient outcomes—our mission is bold, and we’re just getting started.

A huge thank you to the LSI team for bringing the medtech community together to spark real conversations and real progress.

About CraniUS

About CraniUS™

CraniUS™ was founded May 2021 in Baltimore, MD, as a byproduct of the emerging field known as “Neuroplastic and Reconstructive Surgery”, through the vision, insight, and pioneering work of Dr. Chad Gordon. CraniUS™ has raised over $24M to date, been issued 7 patents, and is currently in the midst of a Series B raise.

The NeuroPASS™ device is currently in the pre-clinical development stage and is not yet commercially available. It is on the pathway to clinical studies, and any information provided is subject to change as research progresses.